Follow
Magle Chemoswed Holding AB
Nasdaq First North GM (Sweden)
Magle Chemoswed Holding AB is a contract development and manufacturing organization that serves companies in the pharmaceutical and medical device industry on a contract basis. It provides comprehensive services from product development through product manufacturing. The company's products portfolio includes Warfarin sodium, Melperone hydrochloride, Isradipine, Amantadine sulfate, and Benserazide hydrochloride.
Sector:
HEALTH CARE
>
Biotechnology
Healthcare
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
MAGLE
SE0014401014
Nasdaq First North GM
Sweden (SE)
Details of share in Magle Chemoswed Holding AB with ticker MAGLE
Status
Active
Order book id
Amount of instruments
10 000 000
Par value
Market cap
Currency
SEK
Segment
First North
First trading date
30 Jun 2020
Terms
Type
Price
Pre-money valuation
Time
Files
IPO
20.00 SEK
200M SEK
05 Jun - 17 Jun 2020
IPO in Magle Chemoswed Holding AB
People
Number of Employees
70 people
Justin Pierce
CEO
Hans Henrik Lidgard
Chairman of the board
Sven Christer Nilsson
Board member
Mats Pettersson
Board member
Malin Malmsjö
Board member
Hedda Lidgard
Board member
Julia Kamber
Board member
Ingela Fritzon
Board member
Simon Mårtensson
Board member
Company Details
Sector
HEALTH CARE

Address
Agneslundsvägen 27
Zip code
212 15
City/district
Malmö
Country
Sweden (SE)
Registration number
5565578944
LEI code
549300NZ7FAV26JVB719
First trade date
30 Jun 2020
Registration date
10 Jul 1998
Short name
Magle Chemoswed

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date